Philippe Aftimos

7.6k total citations · 2 hit papers
144 papers, 3.1k citations indexed

About

Philippe Aftimos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Philippe Aftimos has authored 144 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 42 papers in Cancer Research. Recurrent topics in Philippe Aftimos's work include HER2/EGFR in Cancer Research (45 papers), Advanced Breast Cancer Therapies (40 papers) and Cancer Treatment and Pharmacology (26 papers). Philippe Aftimos is often cited by papers focused on HER2/EGFR in Cancer Research (45 papers), Advanced Breast Cancer Therapies (40 papers) and Cancer Treatment and Pharmacology (26 papers). Philippe Aftimos collaborates with scholars based in Belgium, United States and France. Philippe Aftimos's co-authors include Ahmad Awada, Martine Piccart, Christos Sotiriou, Michail Ignatiadis, David Venet, Evandro de Azambuja, Sylvie Rottey, Françoise Rothé, Yacine Barèche and Elisabeth G.E. de Vries and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Philippe Aftimos

133 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Christian Rolfo, Sylvie Rottey et al. profile →
Delivering precision oncology to patients with cancer

2022 197 citations Joaquı́n Mateo, Lotte Steuten et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Aftimos Belgium	25	1.9k	934	809	785	690	144	3.1k
Valentina Boni Spain	29	2.3k 1.2×	1.0k 1.1×	772 1.0×	771 1.0×	771 1.1×	189	3.4k
Ann Knoop Denmark	27	1.8k 0.9×	912 1.0×	517 0.6×	1.3k 1.6×	391 0.6×	116	2.7k
Paul Frankel United States	34	1.9k 1.0×	1.8k 1.9×	967 1.2×	658 0.8×	404 0.6×	214	4.1k
Stacy L. Moulder United States	32	2.5k 1.3×	1.4k 1.5×	922 1.1×	1.3k 1.6×	589 0.9×	141	3.9k
Laura M. Spring United States	27	2.2k 1.2×	835 0.9×	1.3k 1.7×	1.2k 1.5×	402 0.6×	132	3.4k
Iain R. Macpherson United Kingdom	21	1.1k 0.6×	823 0.9×	449 0.6×	603 0.8×	383 0.6×	82	2.4k
Toru Mukohara Japan	28	2.3k 1.2×	1.7k 1.8×	1.7k 2.0×	577 0.7×	448 0.6×	128	4.1k
Jennifer R. Diamond United States	26	2.0k 1.1×	998 1.1×	756 0.9×	469 0.6×	400 0.6×	136	3.0k
Steven R. Olsen United States	17	3.1k 1.6×	921 1.0×	884 1.1×	715 0.9×	1.4k 2.0×	23	4.0k
Amado J. Zurita United States	29	1.5k 0.8×	1.5k 1.6×	1.6k 2.0×	989 1.3×	402 0.6×	144	3.3k

Countries citing papers authored by Philippe Aftimos

Since Specialization

Citations

This map shows the geographic impact of Philippe Aftimos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Aftimos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Aftimos more than expected).

Fields of papers citing papers by Philippe Aftimos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Aftimos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Aftimos. The network helps show where Philippe Aftimos may publish in the future.

Co-authorship network of co-authors of Philippe Aftimos

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Aftimos. A scholar is included among the top collaborators of Philippe Aftimos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Aftimos. Philippe Aftimos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maes, Brigitte, Pieter‐Jan Volders, Guy Froyen, et al.. (2025). Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population. JAMA Network Open. 8(12). e2548538–e2548538.

Joris, Sofie, David Creytens, Sylvie Rottey, et al.. (2025). Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review – an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need. Acta Oncologica. 64. 1295–1306.

Martins-Branco, Diogo, Philippe Aftimos, Brooke Pereira, et al.. (2024). 355P EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study. Annals of Oncology. 35. S365–S366. 1 indexed citations

Amato, Ottavia, Laurence Buisseret, Géraldine Gebhart, et al.. (2023). PIK3CAcopy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. Molecular Case Studies. 9(2). a006255–a006255. 5 indexed citations

Neven, Patrick, Neil Stahl, María Vidal, et al.. (2023). 273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2. Annals of Oncology. 34. S292–S293. 4 indexed citations

Aftimos, Philippe, Kevin Punie, Lore Decoster, et al.. (2023). 181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative. Annals of Oncology. 34. S253–S254.

Li, Bob T., Funda Meric‐Bernstam, Aditya Bardia, et al.. (2023). 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Annals of Oncology. 34. S459–S460. 19 indexed citations

Joris, Sofie, Hannelore Denys, Joëlle Collignon, et al.. (2023). Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open. 8(6). 102041–102041. 18 indexed citations

Marta, Guilherme Nader, Chiara Molinelli, Véronique Debien, et al.. (2023). Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment. Therapeutic Advances in Medical Oncology. 15. 2628415–2628415. 17 indexed citations

10.

Martins-Branco, Diogo, Guilherme Nader Marta, Chiara Molinelli, et al.. (2023). Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis. European Journal of Cancer. 194. 113358–113358. 7 indexed citations

11.

Mateo, Joaquı́n, Lotte Steuten, Philippe Aftimos, et al.. (2022). Delivering precision oncology to patients with cancer. Nature Medicine. 28(4). 658–665. 197 indexed citations breakdown →

12.

Schöffski, Patrick, Ahmad Awada, Mike F. Burbridge, et al.. (2022). First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. European Journal of Cancer. 169. 135–145. 21 indexed citations

13.

Hellmann, Matthew D., Nicoletta Bivi, Boris Calderón, et al.. (2021). Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clinical Cancer Research. 27(10). 2773–2781. 84 indexed citations

14.

Krayem, Mohammad, Philippe Aftimos, Ahmad Najem, et al.. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers. 12(2). 512–512. 15 indexed citations

15.

Delord, Jean‐Pierre, Antoîne Italiano, Ahmad Awada, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology. 16(1). 37–46. 8 indexed citations

16.

Lebbé, Célèste, Antoîne Italiano, Nadine Houédé, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology. 16(1). 47–57. 10 indexed citations

17.

Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations

18.

Lonez, Caroline, Bikash Verma, Alain Hendlisz, et al.. (2017). Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 7(11). e017075–e017075. 42 indexed citations

19.

Aftimos, Philippe, Lieveke Ameye, Christiane Jungels, et al.. (2016). Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. European Journal of Cancer. 60(29). 117–124. 20 indexed citations

20.

Salgado, Roberto, Philippe Aftimos, Christos Sotiriou, & Christine Desmedt. (2014). Evolving paradigms in multifocal breast cancer. Seminars in Cancer Biology. 31. 111–118. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact